Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07298330 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 29, 2026 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised at 27 of 27 sites
    v4
  2. Lead sponsor: Bluejay Therapeutics, Inc. to Mirum Pharmaceuticals, Inc.v3
  3. Study sites: 10 to 27
    • Start date changed from estimate of Dec 2025 to Jan 14, 2026
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 3, global, randomized, open-label, multicenter trial designed to evaluate the safety and efficacy of chronic treatment with brelovitug (BJT-778) for chronic hepatitis delta virus (HDV) infection. The objective of this study is to test the safety and effectiveness of brelovitug compared to delayed treatment.
Trial Details
NCT Number NCT07298330
Lead Sponsor Mirum Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Chronic Hepatitis D Infection
Related terms Hepatitis D
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov